For years scientists at Canada's National Microbiology Laboratory struggled to figure out how to test whether a vaccine developed at the Winnipeg lab would prevent people from contracting Ebola.
Now, finally, three studies in West Africa may provide that answer.
The World Health Organization and several partners announced Thursday they will start testing the vaccine in Guinea in a trial designed to prove whether it is effective. The trial will begin Saturday.
Later this month, the U.S. Centers for Disease Control expects to launch a trial of the vaccine — now licensed to biotech company NewLink Genetics and pharmaceutical giant Merck — in Sierra Leone.
Click here for the full story.